Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd (NASDAQ:ADXNGet Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 8,700 shares, a growth of 222.2% from the January 15th total of 2,700 shares. Based on an average daily volume of 10,800 shares, the short-interest ratio is currently 0.8 days. Currently, 0.9% of the shares of the stock are short sold.

Addex Therapeutics Stock Up 3.2 %

Shares of NASDAQ:ADXN traded up $0.32 during trading on Monday, hitting $10.20. 152 shares of the company were exchanged, compared to its average volume of 12,870. The business’s 50 day moving average is $7.43 and its 200-day moving average is $7.84. The company has a market capitalization of $10.10 million, a P/E ratio of -0.53 and a beta of 1.65. Addex Therapeutics has a 1-year low of $5.00 and a 1-year high of $45.60.

Addex Therapeutics (NASDAQ:ADXNGet Free Report) last posted its quarterly earnings data on Wednesday, November 29th. The company reported ($4.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.00) by ($0.07). The company had revenue of $0.37 million during the quarter, compared to analyst estimates of $0.70 million. Addex Therapeutics had a negative net margin of 550.78% and a negative return on equity of 236.83%. As a group, sell-side analysts anticipate that Addex Therapeutics will post -17.2 earnings per share for the current year.

Institutional Trading of Addex Therapeutics

A hedge fund recently raised its stake in Addex Therapeutics stock. Armistice Capital LLC grew its holdings in shares of Addex Therapeutics Ltd (NASDAQ:ADXNFree Report) by 103.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 537,000 shares of the company’s stock after acquiring an additional 273,000 shares during the period. Armistice Capital LLC owned 65.33% of Addex Therapeutics worth $206,000 as of its most recent SEC filing.

Addex Therapeutics Company Profile

(Get Free Report)

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction.

See Also

Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with's FREE daily email newsletter.